Constellation Pharmaceuticals has priced an underwritten public offering of 5.5 million shares of its common stock at the rate of $35.00 per share. The company expects to earn total gross proceeds of $192.5 million, without deduction of underwriting discounts, commissions, taxes and other costs payable by the company. All of the shares of the common stock involved in public offering are being offered by Constellation Pharmaceuticals. Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company which develops novel therapeutics and uses its expertise in epigenetics to discover and develop.
According to the terms and conditions, the underwriters has a 30-day option to purchase up to 825,000 additional shares of company’s common stock at the public offering price with the deduction of underwriting discount and commissions. The offering is scheduled to close on June 19, 2020 according to the satisfactory of the customary closing conditions.
Constellation has J.P. Morgan, Jefferies, Cowen and RBC Capital Markets as joint book-running managers for the company’s offering. While SunTrust Robinson Humphrey is working as lead manager and Baird is working as co-manager in this offering.
Constellation has offered these shares in accord to an automatically effective registration statement that the company filed with the SEC on December 9, 2019. Company has filed the preliminary prospectus postscript with where it has described the terms of the offering with SEC and is available on the SEC’s website at www.sec.gov. Company will file a final prospectus supplement to SEC related to the offering.
Constellation Pharmaceuticals, Inc. (CNST) trades at NASDAQ. Its stock has market value of $32.03 per share as of Wednesday trade with market cap of $1.33 billion after the increase of 62.75% in last quarter and a decline of 32.01% in 2020.
Jamie French is an author, journalist and CEO of themostactivestocks.review, a leading stocks and markets website. He has more than 5 years of experience in institutional investment markets, including fixed income, equities, derivatives and real estate. He has a Bachelor in Business Administration with a major in Finance. He bought his first stocks in a private business at age 15 and made his first public stock trade at 23. David has always been interested in the stock market and how it behaves.
As the dad of two children, he’s made saving money and investing for them a high priority. Over many years of investing, he has made some wise choices and he’s made many mistakes. But he’s learned from both. Mr. Jamie observations and experience give him the insight to stock market patterns and the investor behaviors that create them.
Address: 4570 Barrington Court, Joiner, Arkansas
Phone number: 870-537-3633
Email: JamieFrench@thepostwired.com